Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58

To assess the associations between baseline glucose‐lowering agents (GLAs) and cardiorenal outcomes with dapagliflozin versus placebo in the DECLARE‐TIMI 58 study.

[1]  C. Cannon,et al.  The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. , 2020, International journal of cardiology.

[2]  R. Glynn,et al.  35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy , 2020 .

[3]  B. Lewis,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD , 2020 .

[4]  Lawrence A Leiter,et al.  Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. , 2020, The lancet. Diabetes & endocrinology.

[5]  R. DeFronzo,et al.  Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes , 2020, Diabetes Care.

[6]  Deepak L. Bhatt,et al.  Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial , 2020, Diabetes, obesity & metabolism.

[7]  E. Braunwald,et al.  Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[8]  L. Blonde,et al.  Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial , 2020, Diabetes, obesity & metabolism.

[9]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[10]  G. Schernthaner,et al.  The right place for Metformin today. , 2019, Diabetes research and clinical practice.

[11]  Deepak L. Bhatt,et al.  The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. , 2019, Cell metabolism.

[12]  R. Holman,et al.  Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial , 2019, Cardiovascular Diabetology.

[13]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[14]  A. Aldosari,et al.  Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials. , 2019, Canadian journal of diabetes.

[15]  B. Zinman,et al.  Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy? , 2019, Diabetes, obesity & metabolism.

[16]  W. E. Sanabria,et al.  Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. , 2019, Lancet.

[17]  B. Zinman,et al.  Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[18]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[19]  V. Fonseca,et al.  Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. , 2019, Journal of diabetes and its complications.

[20]  Deepak L. Bhatt,et al.  DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL , 2019, Journal of the American College of Cardiology.

[21]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. , 2019, Circulation.

[22]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[23]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[24]  M. Pencina,et al.  Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial , 2019, JAMA.

[25]  K. Tuttle,et al.  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. , 2018, The lancet. Diabetes & endocrinology.

[26]  H. Heerspink,et al.  Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. , 2018, Kidney international.

[27]  Marc P. Bonaca,et al.  The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial , 2018, American heart journal.

[28]  B. Ludvik,et al.  Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. , 2018, The lancet. Diabetes & endocrinology.

[29]  M. Packer.  Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes? , 2018, The American journal of medicine.

[30]  Deepak L. Bhatt,et al.  DECLARE‐TIMI 58: Participants’ baseline characteristics , 2018, Diabetes, obesity & metabolism.

[31]  D. Bolignano,et al.  Exploring the effects of DPP‐4 inhibitors on the kidney from the bench to clinical trials , 2017, Pharmacological research.

[32]  R. DeFronzo.  Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor , 2017, Diabetes, obesity & metabolism.

[33]  E. Hoorn,et al.  GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes , 2017, Nature Reviews Nephrology.

[34]  S. Jabbour.  Durability of response to dapagliflozin: a review of long-term efficacy and safety , 2017, Current medical research and opinion.

[35]  V. Perkovic,et al.  Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial , 2017, Diabetes, obesity & metabolism.

[36]  R. DeFronzo,et al.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition , 2017, Nature Reviews Nephrology.

[37]  É. Hardy,et al.  Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[38]  Deepak L. Bhatt,et al.  Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial , 2016, Diabetes Care.

[39]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.